Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B

Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in its investigational stem cell therapy, Lomecel-B. The ... Read More